Formation of solid lipid nanoparticle (SLN)-gene vector complexes for transfection of mammalian cells in vitro

Cold Spring Harbor Protocols

Volumn 7, Issue 3, 2012, Pages 357-360

  Rudolph, Carsten ^a   Rosenecker, Joseph ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; POLYETHYLENEIMINE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; SORBITAN TRIOLEATE; TRANSACTIVATOR PROTEIN; DRUG CARRIER; LIPOSOME; NANOPARTICLE;

ARTICLE; CONCENTRATION (PARAMETERS); CYTOTOXICITY; GENE VECTOR; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; INTERMETHOD COMPARISON; MAMMAL CELL; MASS SPECTROMETRY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRECIPITATION; ANIMAL; CELL CULTURE; GENETICS; HUMAN; MAMMAL; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; PLASMID;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

ANIMALS; CELLS, CULTURED; DRUG CARRIERS; GENETIC VECTORS; HUMANS; LIPOSOMES; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES; PLASMIDS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSFECTION;

EID: 84857878935     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.prot068122     Document Type: Article

References (16)

1. Bragonzi A, Dina G, Villa A, Calori G, Biffi A, Bordignon C, Assael BM, Conese M. 2000. Biodistribution and transgene expression with non-viral cationic vector/DNA complexes in the lungs. Gene Ther 7: 1753-1760.
2. Dingler A, Gohla S. 2002. Production of solid lipid nanoparticles (SLN): Scaling up feasibilities. J Microencapsul 19: 11-16.
3. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. 1994. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci 91: 664-668.
4. Frankel AD, Pabo CO. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193.
5. Freitas C, Müller RH. 1999. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 47: 125-132.
6. Gebhart CL, Kabanov AV. 2001. Evaluation of polyplexes as gene transfer agents. J Control Release 73: 401-416.
7. Mehnert W, Mader K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Delivery Rev 47: 165-196.
8. Müller RH, Dingler A, Schneppe T, Gohla S. 2000a. Large scale production of solid lipid nanoparticles (SLNTM) and nanodispersions (Disso-Cubes™). In Handbook of pharmaceutical controlled release technology (ed. Wise D), pp. 359-376. Marcel Dekker, New York.
9. Müller RH, Mader K, Gohla S. 2000b. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
10. Olbrich C, Bakowsky U, Lehr CM, Müller RH, Kneuer C. 2001. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 77: 345-355.
11. Plank C, Tang MX, Wolfe AR, Szoka FC, 1999. Branched cationicpeptides for gene delivery: Role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther 10: 319-332.
12. Rudolph C, Plank C, Lausier J, Schillinger U, Müller RH, Rosenecker J. 2003. Oli-gomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 8: 11411-11418.
13. Schwarz C, Mehnert W. 1997. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (Sln). Int J Pharm 157: 171-179.
14. Schwarz C, Mehnert W, Lucks JS, Müller RH. 1994. Solid lipid nanoparticles (Sln) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release 30: 83-96.
15. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. 2004. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 57: 155-162.
16. Truant R, Cullen BR. 1999. The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin β-dependent nuclear localization signals. Mol Cell Biol 19: 1210-1217.